NBTX:NASDAQNanobiotix S.A. Analysis
Data as of 2026-04-19 - not real-time
$33.79
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Nanobiotix is trading in a clear bullish technical environment – the short‑term moving average sits above the intermediate and long‑term averages, momentum indicators are positive and price is holding above key support while approaching resistance.
Fundamentally the company remains a high‑risk, high‑cost clinical‑stage biotech with extreme valuation multiples, negative cash flow, and a debt load that dwarfs its cash position. Recent investor communications signal an upcoming earnings release and continued partnership activity in Asia, which could provide short‑term catalysts but also underscore the reliance on trial outcomes and regulatory approvals.
Fundamentally the company remains a high‑risk, high‑cost clinical‑stage biotech with extreme valuation multiples, negative cash flow, and a debt load that dwarfs its cash position. Recent investor communications signal an upcoming earnings release and continued partnership activity in Asia, which could provide short‑term catalysts but also underscore the reliance on trial outcomes and regulatory approvals.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish technical setup with momentum indicators turning positive
- Upcoming earnings call that may provide fresh data on trial progress
- Strong analyst sentiment reflected in a strong‑buy recommendation
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Continued cash burn and a balance sheet that remains heavily leveraged
- Valuation remains far above industry averages, limiting upside
- Clinical trial outcomes and regulatory approvals remain uncertain
Long Term
> 3 yearsCautious
Model confidence: 5/10
Key Factors
- Persistent lack of profitability and negative cash flow trends
- Overvaluation could compress sharply if trial milestones are missed
- High sector and regulatory risk inherent to late‑stage biotech
Key Metrics & Analysis
Financial Health
Profit Margin-73.52%
P/E Ratio462.3
ROA-10.06%
P/B Ratio-20.4
Op. Cash Flow$-33422000
Free Cash Flow$-7894125
Industry P/E26.2
Technical Analysis
TrendBullish
RSI57.0
Support$28.40
Resistance$34.65
MA 20$31.26
MA 50$30.06
MA 200$19.63
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21
Valuation
Target Price$33.36
Upside/Downside-1.27%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.56
Volatility99.91%
Sector RiskHigh
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.